Risk factors for spontaneous abortion following hepatitis E vaccination during and shortly before pregnancy: Further analysis from a cluster-randomized trial

A Asma Binte Aziz F Faisal Ahmmed K Kassa Haile K Kelvin Kering S Susanne Dudman C Cathinka Halle Julin J Joakim Øverbø A Ashraful Islam Khan A Afroza Akter B Beatrice Atieno Ongadi B Benjamin Ngugi C Cecilia Kathure Mbae E Edlawit Mesfin F Fahima Chowdhury (Mucosal Immunology and Vaccinology Unit, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh) F Farhana Khanam J Joo-Young Esther Lee J Justin Im M Martin Mwebia Bundi M Md Golam Firoj M Md Taufiqul Islam M Moses Mwangi N Natasha Y. Rickett S Sadia Isfat Ara M Meseret Gebre Behute S Se Eun Park S Suneth Agampodi S Samuel Kariuki S Suman Kanungo D Deok Ryun Kim F Firdausi Qadri K Khalequ Zaman J John D Clemens

Abstract

Background A recent randomized trial of Hepatitis E Vaccine (HEV239) found an elevated risk of spontaneous abortion (SAB) in women given HEV239 during or within ninety days before pregnancy. Here we present additional analyses to better understand this risk. Methods We investigated whether maternal risk profiles of SAB or gestational age at SAB differed between women receiving HEV239 versus control Hepatitis B vaccine (HBV). We also assessed whether HEV239-vaccinated women who experienced SABs had distinct short-term adverse reactions compared to HEV239-vaccinated women who had live births, exploring potential inflammatory mechanisms. Finally, we assessed maternal exposure to HEV239 in narrowly defined pre-last menstrual period (LMP) windows to more precisely demarcate pre-LMP at which HEV-239 vaccination was associated with an elevated risk of SAB. Chi-square tests and Mann-Whitney U tests were performed for bivariate comparisons. Poisson models were used for multivariable analyses. Findings Baseline maternal risk factors for SAB (age, body mass index, parity, and histories of SAB, hypertension, or diabetes) were similar between the SABs in HEV239 and HBV groups. Median gestational age at SAB was comparable (10.5 weeks [IQR 10-13] for HEV239 vs. 11 weeks [IQR 9-12.2] for HBV, p = 0.783). No increased short-term adverse events (pain: 9% vs. 9%; fever: 2% vs. 1%) were observed among HEV239 recipients who experienced SABs compared to those who did not. An elevated risk of SAB was observed in HEV239 recipients vaccinated 31–60 days pre-LMP (Relative Risk 4.3 [95% CI 1.3–19.3], p = 0.026). Interpretation Our analyses did not uncover associations pointing to a biological mechanism underlying the original observation of an increased SAB rate connected to HEV239 vaccination shortly before or during pregnancy. Targeted studies such as placental examinations and genetic testing are needed to investigate potential mechanisms.

Article Details

Journal PLoS ONE
Volume / Issue Vol. 21, Issue 4
Published April 10, 2026
Pages e0345974
ISSN 1932-6203
Publisher Public Library of Science

Journal Info

PLoS ONE

Public Library of Science

ISSN: 1932-6203 Open Access Health Sciences

Authors (32)

A

Asma Binte Aziz

F

Faisal Ahmmed

K

Kassa Haile

K

Kelvin Kering

S

Susanne Dudman

C

Cathinka Halle Julin

J

Joakim Øverbø

A

Ashraful Islam Khan

A

Afroza Akter

B

Beatrice Atieno Ongadi

B

Benjamin Ngugi

C

Cecilia Kathure Mbae

E

Edlawit Mesfin

F

Fahima Chowdhury

Mucosal Immunology and Vaccinology Unit, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh

F

Farhana Khanam

J

Joo-Young Esther Lee

J

Justin Im

M

Martin Mwebia Bundi

M

Md Golam Firoj

M

Md Taufiqul Islam

M

Moses Mwangi

N

Natasha Y. Rickett

S

Sadia Isfat Ara

M

Meseret Gebre Behute

S

Se Eun Park

S

Suneth Agampodi

S

Samuel Kariuki

S

Suman Kanungo

D

Deok Ryun Kim

F

Firdausi Qadri

K

Khalequ Zaman

J

John D Clemens